Author:
da Silva Gama Zenewton André,Medeiros Wilton Rodrigues,Saturno-Hernández Pedro Jesus,de Meneses Sousa Kelienny,Mello Matheus Silva,de Lima Vale Érico,de Souza Rosendo Tatyana Maria Silva,da Silva Edna Marta Mendes,de Freitas Marise Reis
Abstract
Abstract
Background
Preeclampsia is a relatively frequent condition during pregnancy and childbirth. The administration of magnesium sulphate as a prophylactic and treatment measure is an evidence-based practice for eclampsia; however, it is not consistently used, compromising the health of pregnant women. This study aimed to assess compliance with recommendations of the International Society for the Study of Hypertension in Pregnancy (ISSHP) for the use of MgSO4 in pregnant women with preeclampsia, before and after the implementation of the World Health Organization Safe Childbirth Checklist (SCC).
Methods
This quasi-experimental study was conducted between July 2015 and July 2016 at a third-level maternity hospital in northeastern Brazil, where the SCC was implemented. Compliance (underuse and overuse of MgSO4) was assessed in biweekly samples of 30 deliveries assessed 6 months before and 6 months after SCC implementation, using indicators based on international guidelines. A total of 720 deliveries were assessed over 1 year using an ad hoc application for reviewing medical records. Aggregated adequate use was estimated for the study period, and the time series measurements were compared to a control chart to assess change.
Results
The incidence of preeclampsia was 39.9% (287/720). Among these, 64.8% (186/287) had severe signs or symptoms and needed MgSO4. Underuse (no prescription when needed) of MgSO4 was observed in 74.7% (139/186) of women who needed the drug. Considering all women, non-compliance with the prescription protocol (underuse and overuse) was 20.0% (144/720). After introducing the SCC, the use of MgSO4 in women with preeclampsia with severe features increased from 19.1 to 34.2% (p = 0.025). Longitudinal analysis showed a significant (p < 0.05) ascending curve of adequate use of MgSO4 after the SCC was implemented.
Conclusions
Compliance with recommendations for the use of MgSO4 in preeclampsia was low, but improved after implementation of the SCC. Interventions to improve compliance based on diagnosis and treatment reminders may help in the implementation of this good practice.
Funder
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynaecology
Reference35 articles.
1. World Health Organization (WHO). Recommendations for prevention and treatment of pre-eclampsia and eclampsia. 2011. Available from: http://whqlibdoc.who.int/publications/2011/9789241548335_eng.pdf. [Accessed 30 July 2018].
2. Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Heal. 2014;2(6):323–33.
3. Assis TR, Viana FP, Rassi S. Estudo dos principais fatores de risco maternos nas síndromes hipertensivas da gestação. Arq Bras Cardiol. 2008;91(1):11–7.
4. Oliveira A, Graciliano N. Síndrome hipertensiva da gravidez e diabetes mellitus gestacional em uma maternidade pública de uma capital do Nordeste brasileiro, 2013: prevalência e fatores associados. Epidemiologia e Serviços de Saúde. 2015;24(3):441–51.
5. Magee LA, Pels A, Helewa M, Rey E, Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014;4(2):105–45.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献